BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

...INDICATION: Solid tumors Cell culture and mouse studies suggest RvD1, RvD2 and RvE1 could help treat...
...of RvD1, RvD2 or RvE1 decreased tumor growth compared with vehicle. Also in the models, RvE1...
...Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard Medical School Resolvin D1 (RvD1) Resolvin D2 (RvD2) Resolvin E1 (RvE1) Melanoma...
BioCentury | Nov 30, 2017
Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

...of macrophages. Panigrahy's team showed efficacy for resolvin D1 (RvD1), resolvin D2 (RvD2) and resolvin E1 (RvE1...
...2010, Auven Therapeutics Management LLLP acquired an exclusive license to a topical synthetic analog of RvE1...
...LLLP Beth Israel Deaconess Medical Center Brigham and Women's Hospital Harvard Medical School Resolvyx Pharmaceuticals Inc. Resolvin D1 Resolvin D2 (RvD2) Resolvin E1 (RvE1) Cancer...
BioCentury | Nov 19, 2015
Distillery Therapeutics

Therapeutics: Resolvin E1 (RvE1)

...RvE1 could help treat dermal inflammation. In a mouse model of contact hypersensitivity to dinitrofluorobenzene, RvE1...
...vehicle. Next steps could include testing RvE1 in other models of dermal inflammation. TARGET/MARKER/PATHWAY: Resolvin E1 (RvE1...
BioCentury | Jan 17, 2011
Company News

Celtic Therapeutics Holdings L.P., Resolvyx deal

...milestones. Celtic will fund all further development costs of the topical synthetic analog of resolvin E1 (RvE1...
BioCentury | Nov 1, 2010
Finance

Celtic's Big Top Off

...RX-10045 for all eye indications. Phase III testing of the topical synthetic analog of resolvin E1 (RvE1...
BioCentury | Nov 1, 2010
Company News

Celtic Therapeutics Holdings L.P., Resolvyx deal

...exclusive, worldwide rights to RX-10045 for all ophthalmic indications. The topical synthetic analog of resolvin E1 (RvE1...
BioCentury | Oct 27, 2010
Company News

Resolvyx grants Celtic RX-10045 option

...RX-10045 for all eye indications. Phase III testing of the topical synthetic analog of resolvin E1 (RvE1...
BioCentury | May 17, 2010
Clinical News

Resolvyx preclinical data

...treat asthma and other inflammatory diseases. Resolvyx Pharmaceuticals Inc. , Bedford, Mass. Product: RX-10001 (formerly RvE1...
BioCentury | Apr 22, 2010
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Resolvin E1 (RvE1); resolvin D1 (RvD1...
...pain. In mouse models of chemically induced acute and chronic inflammatory pain, nanogram doses of RvE1...
...pain and chronic pain. Resolvyx Pharmaceuticals Inc.'s RX-10045, an isopropyl ester prodrug of a synthetic RvE1...
BioCentury | Apr 22, 2010
Targets & Mechanisms

Promoting pain resolution

...Women's. In several mouse models of acute and chronic inflammatory pain, nanogram injections of resolvin E1 (RvE1...
...are important for protecting the body from potentially damaging stimuli. The team also showed that RvE1...
...in pain, including CNS neurons that express chemokine-like receptor 1 ( CMKLR1 ; ChemR23), which RvE1...
Items per page:
1 - 10 of 23